CTI opens in Singapore with further expansion in Asia planned

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/KCHL)
(Image: Getty/KCHL)
CTI Clinical Trial and Consulting Services (CTI) has opened a new office in Singapore – a location that will enable the CRO to attract and retain talent as it continues expansion in Asia.

The offices will operate as a wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Singapore Pte. Ltd.

The contract research organization (CRO) has opened more than a dozen offices over the past few years, including new offices in Taipei, Taiwan and Tokyo, Japan in June of 2017.

Pat Earley, vice president, International, CTI, told us the company chose to expand into Singapore because “it is a critically important location for cutting-edge, innovative research including cell and gene therapy which CTI specializes in​.”

The leading academic centers and regulatory authorities have displayed a willingness to develop very open partnerships with pharmaceutical companies, biotechnology companies, and CROs, making Singapore a very desirable county for us to do business in​,” he said.

The specific office location was chosen due to its proximity to the Singapore business district and access to medical centers and transportation.

Its central location will help us attract and retain a qualified workforce as we expand in the area​,” added Earley.

According to the company, additional expansions are planned in Asia over the next 12 to 18 months.

The expansion news come on the heels of CTI’s acquisition of Eurotrials in December ​ – a deal that created “one of the 20 largest CROs in the world​,” Timothy J. Schroeder, CTI founder and CEO said at the time.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers